I hope to disabuse the hon. Gentleman of such suspicions. The cost benefit analysis is important, and we hope to announce the details shortly. We will certainly make all the information available. However, there are other issues to be considered—such as deciding the precise formula, training, and the relationship between nurse and general practitioner prescribing. It is a complex matter, but the concept has strong support and we shall carry forward that work.